Lixisenatide for parkinson disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Feb 2018: Trial registered, NCT03439943
  2. 13 Jun 2018: Trial started, NCT03439943

The trials

NCT03439943: Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease

State
Completed
Phase
Phase 2
People
156 taking part
Started
13 Jun 2018
Primary completion
15 Apr 2021
Arms
Lixisenatide
Results
None posted
  1. 20 Feb 2018: Trial registered
  2. 13 Jun 2018: Trial started
  3. 15 Apr 2021: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Lyxumia, SOLIQUA 100/33 COMPONENT LIXISENATIDE.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.